Business Context and Reporting Period
This Form 8-K reports on the results of the 2017 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on June 14, 2017. The meeting took place at the company's principal executive offices in Beverly Hills, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 18,185,184 shares (of 21,399,019 entitled to vote) participated in the meeting. The following proposals were approved:
- Director Elections: All seven nominees were elected to the Board of Directors. The highest "For" vote was for David B. Musket (12,437,414), and the lowest was for Frank Litvack, M.D. (12,075,564). All nominees received 5,722,454 broker non-votes.
- Auditor Ratification: The appointment of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017, was ratified with 17,878,792 votes "For" and 83,134 votes "Against".
- Executive Compensation: The non-binding advisory vote to approve the compensation of named executive officers passed with 12,331,098 votes "For" and 81,828 votes "Against".
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves solely as a disclosure of the voting outcomes.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 21, 2017, for detailed biographies of the elected directors and the specific compensation details approved.
- Confirm the total number of shares outstanding and the quorum status based on the 18,185,184 shares present.
- Review the company's subsequent filings for the official appointment of the new audit firm for the 2017 fiscal year.